Apixaban Prevents VTE in Cancer Patients Initiating Chemotherapy

Share this content:
Apixaban Prevents VTE in Cancer Patients Initiating Chemotherapy
Apixaban Prevents VTE in Cancer Patients Initiating Chemotherapy

FRIDAY, Dec. 14, 2018 (HealthDay News) -- Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban versus placebo, according to a study published online Dec. 4 in the New England Journal of Medicine.

Marc Carrier, M.D., from the University of Ottawa in Canada, and colleagues conducted a randomized, double-blind, placebo-controlled clinical trial to examine the efficacy and safety of apixaban for thromboprophylaxis in ambulatory patients with cancer starting chemotherapy who were at intermediate-to-high risk for venous thromboembolism. A total of 574 patients underwent randomization; 563 were included in the modified intention-to-treat analysis.

The researchers found that venous thromboembolism occurred in 4.2 and 10.2 percent of patients in the apixaban and placebo groups, respectively (hazard ratio, 0.41; 95 percent confidence interval, 0.26 to 0.65). Major bleeding occurred in 3.5 and 1.8 percent of patients in the apixaban and placebo groups, respectively, in the modified intention-to-treat analysis (hazard ratio, 2; 95 percent confidence interval, 1.01 to 3.95). Major bleeding occurred in 2.1 and 1.1 percent of patients in the apixaban and placebo groups, respectively, during the treatment period (hazard ratio, 1.89; 95 percent confidence interval, 0.39 to 9.24).

"Anticoagulants are commonly used to prevent blood clots in other high-risk groups, but the traditional thinking has been that these drugs would cause too much bleeding in people with cancer," Carrier said in a statement. "Our study shows that if you select the right patients and use a relatively low dose of a direct oral anticoagulant, the benefits easily outweigh the risks."

The study was funded in part by Bristol-Myers Squibb-Pfizer Alliance; Bristol-Myers Squibb and Pfizer manufacture apixaban.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Progress in HIV Prevention Has Stalled in the United States

CDC: Progress in HIV Prevention Has Stalled in ...

Agency says effective HIV prevention, treatment not reaching those who could most benefit

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in Children

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in ...

All children with sustained unresponsiveness ingested concentrated and baked egg

Prenatal Vitamin Intake in Early Pregnancy May Cut Autism Risk

Prenatal Vitamin Intake in Early Pregnancy May Cut ...

ASD risk down for children whose mothers took prenatal vitamins during first month of pregnancy

is free, fast, and customized just for you!




Already a member?

Sign In Now »